Detection of Trichophyton rubrum and Trichophyton interdigitale in onychomycosis using monoclonal antibodies against Sub6 (Tri r 2).


Journal

Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 13 07 2018
revised: 08 08 2018
accepted: 21 08 2018
pubmed: 29 8 2018
medline: 5 2 2019
entrez: 29 8 2018
Statut: ppublish

Résumé

Onychomycosis is the most prevalent nail disease and is mainly caused by two dermatophyte species Trichophyton rubrum and Trichophyton interdigitale with a frequency in the range of 80% and 20%, respectively. The secreted protease Sub6 of the subtilisin family, which was never detected in vitro growth conditions, was found to be a robust marker of onychomycosis. The aim of this work was to detect tinea unguium using anti-Sub6 monoclonal antibodies in proteins extracted from clinical nail samples. We produced monoclonal antibodies in mice using recombinant Sub6 as an antigen. Selected monoclonal antibodies were tested by Western blot analysis and ELISA on protein extracts from onychomycosis samples. Several monoclonal antibodies used to quantify Sub6 in proteins extracted from clinical nail samples were produced and characterised. We showed that these antibodies were very specific and allowed the detection of T. rubrum and T. interdigitale in onychomycosis. Sub6 was detected in clinical samples infected by T. rubrum and not detected in nails with trauma and other diseases. Anti-Sub6 monoclonal antibodies could be useful for a rapid diagnosis of tinea unguium and/or therapeutic survey of dermatophyte in onychomycosis by ELISA or an immunochromatography device such as a strip test.

Sections du résumé

BACKGROUND BACKGROUND
Onychomycosis is the most prevalent nail disease and is mainly caused by two dermatophyte species Trichophyton rubrum and Trichophyton interdigitale with a frequency in the range of 80% and 20%, respectively. The secreted protease Sub6 of the subtilisin family, which was never detected in vitro growth conditions, was found to be a robust marker of onychomycosis.
OBJECTIVE OBJECTIVE
The aim of this work was to detect tinea unguium using anti-Sub6 monoclonal antibodies in proteins extracted from clinical nail samples.
METHODS METHODS
We produced monoclonal antibodies in mice using recombinant Sub6 as an antigen. Selected monoclonal antibodies were tested by Western blot analysis and ELISA on protein extracts from onychomycosis samples.
RESULTS RESULTS
Several monoclonal antibodies used to quantify Sub6 in proteins extracted from clinical nail samples were produced and characterised. We showed that these antibodies were very specific and allowed the detection of T. rubrum and T. interdigitale in onychomycosis. Sub6 was detected in clinical samples infected by T. rubrum and not detected in nails with trauma and other diseases.
CONCLUSION CONCLUSIONS
Anti-Sub6 monoclonal antibodies could be useful for a rapid diagnosis of tinea unguium and/or therapeutic survey of dermatophyte in onychomycosis by ELISA or an immunochromatography device such as a strip test.

Identifiants

pubmed: 30152879
doi: 10.1111/myc.12843
doi:

Substances chimiques

Antibodies, Fungal 0
Antibodies, Monoclonal 0
Antigens, Fungal 0
Peptide Hydrolases EC 3.4.-

Banques de données

GENBANK
['LT717086', 'LAU2354']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

32-40

Subventions

Organisme : Galderma R&D

Informations de copyright

© 2018 Blackwell Verlag GmbH.

Auteurs

Bruno Méhul (B)

Galderma R&D, Sophia-Antipolis, France.

Niccolo de Coi (N)

Department of Dermatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Philippe Grundt (P)

Galderma R&D, Sophia-Antipolis, France.

Alexandre Genette (A)

Galderma R&D, Sophia-Antipolis, France.

Johannes J Voegel (JJ)

Galderma R&D, Sophia-Antipolis, France.

Michel Monod (M)

Department of Dermatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH